
    
      Study Type: Interventional Study Design: Two-way crossover, randomized, open-label,
      single-dose, fed, bioequivalence study

      Official Title: A Two-Way Crossover, Open-Label, Single Dose, Fed, Bioequivalence Study of
      Carvedilol 12.5 mg Tablets Versus CoregÂ® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male
      and Female Subjects

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    
  